8-K 1 y74648e8vk.htm FORM 8-K 8-K
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 13, 2009
Electro-Optical Sciences, Inc.
(Exact name of registrant as specified in its charter)
         
Delaware
(State or other jurisdiction
of incorporation) 		  000-51481
(Commission
File Number) 		  13-3986004
(IRS Employer
Identification No.)
     
3 West Main Street, Suite 201,
Irvington, New York
(Address of principal executive offices) 		  10533
(Zip Code)
Registrant’s telephone number, including area code (914) 591-3783
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 8.01 — Other Events
Item 9.01 — Financial Statements and Exhibits
SIGNATURES
EX-99.1: PRESS RELEASE

Table of Contents

Item 8.01 — Other Events
On February 13, 2009, the Registrant issued a press release announcing the results of the MelaFind® clinical trials program. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.
Item 9.01 — Financial Statements and Exhibits
(d) Exhibits.
     
EXHIBIT NO.   DESCRIPTION
 
    
99.1
  Press Release of the Registrant, dated February 13, 2009, titled “Electro-Optical Sciences Announces Positive Top-Line Results from Landmark MelaFind® Pivotal Trial”

 

Table of Contents

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
 
Electro-Optical Sciences, Inc.
 		  
Date: February 13, 2009  By:   /s/ Richard I. Steinhart    
    Chief Financial Officer    
    (Principal Financial Officer)   
 

 

Table of Contents

EXHIBIT INDEX
     
EXHIBIT NO.   DESCRIPTION
 
    
99.1
  Press Release of the Registrant, dated February 13, 2009, titled “Electro-Optical Sciences Announces Positive Top-Line Results from Landmark MelaFind® Pivotal Trial”